Adial's Q2 Loss of $52M and Cash Runway into 2H 2027
ADIL has more than doubled off its 52-week low of $1.31 on light trading volume (0.1× avg).
Summary
Adial Pharmaceuticals posted a Q2 net loss of $52 million, largely due to a non-cash $46.2 million acquired R&D charge, while $28.7 million in cash supports operations into 2H 2027.
Key Events · Earnings and Guidance · ADIL
-
Q2 Net Loss of $52M
A net loss of $52.0 million, or $11.25 per share, was driven by a $46.2 million non-cash acquired in-process R&D charge from the Azora acquisition.
-
Cash Runway into 2H 2027
Cash and equivalents stood at $28.7 million as of June 30, 2026, up from $4.6 million at March 31, 2026, funding operations into the second half of 2027 excluding the $32 million milestone tranche.
-
Stockholders' Deficit of $38.4M
The deficit includes a $23.8 million milestone warrant liability and $38.5 million mezzanine equity from Series A convertible preferred stock, both expected to reclassify to equity upon stockholder approval.
-
AT177 IND Filing Planned 1H 2027
Lead program AT177, an oral AhR agonist for ulcerative colitis, is on track for an IND filing in the first half of 2027, with a Phase 1a trial planned for the second half of 2027.
Analysis · ADIL · Life Sciences
The second quarter delivered a $52 million net loss for Adial, driven by a $46.2 million non-cash charge for acquired in-process R&D from the Azora merger. With $28.7 million in cash, operations are funded into the second half of 2027, excluding a potential $32 million milestone tranche. A stockholders' deficit of $38.4 million and a Nasdaq listing deficiency weigh on the balance sheet, but the financing and pipeline progress offer a path forward.
At the time of this filing, ADIL was trading at $3.08 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8.7M. The 52-week trading range was $1.31 to $10.75. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.